Supplements9 min read
B-complex supplements: one bottle, eight separate decisions
A B-complex turns one supplement choice into several nutrient exposures. Review stress evidence, ingredient overlap and the reason for each dose.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Explore the articles
Find a topic you’re curious about and take a closer look.
Supplements9 min read
Fenugreek and testosterone: the extract and the outcome both matter
Fenugreek trials have measured different extracts and outcomes. Compare positive findings with newer studies and the very uncertain pooled hormone evidence.
Read article
Peptides8 min read
Survodutide in type 2 diabetes: what a 16-week trial can tell us
The early diabetes trial lowered HbA1c and weight, but its experimental schedules and short follow-up matter when interpreting the results.
Read article
Peptides9 min read
Why phase 2 and phase 3 survodutide percentages need context
Why survodutide's 46-week and 76-week results differ, including actual versus assigned dose, placebo response and analysis methods.
Read article
Peptides9 min read
How to read a pemvidutide announcement without losing the clinical meaning
Follow the IMPACT announcements from topline results to the full paper, while keeping biopsy endpoints, digital analyses and later follow-up distinct.
Read article
Peptides9 min read
What eloralintide needs to demonstrate beyond early weight loss
The next eloralintide questions concern durability, diabetes, physical function and safety—not simply a larger weight-loss percentage.
Read article
Peptides9 min read
Petrelintide's early weight result: what 8.6% means
The early 8.6% weight-loss finding came from a small sixteen-week cohort. Its comparator, analysis and exposure explain how to interpret it.
Read article
Peptides9 min read
What patient-reported outcomes add to afamelanotide trials
Patient-reported outcomes reveal what EPP treatment changes in daily life. Understanding questionnaire development, missing data and different domains helps interpret them.
Read article
Peptides9 min read
Could pemvidutide treat liver disease and alcohol use disorder?
One dual agonist is being investigated for several conditions, but liver-fat, biopsy and drinking outcomes answer different questions.
Read article
Peptides9 min read
Thymosin beta-4 for dry eye: what the trial’s main results showed
What thymosin beta-4 eye-drop trials found about comfort, surface staining and why favorable secondary findings do not replace missed main outcomes.
Read article
Peptides9 min read
What ARA-290 sarcoidosis research can tell people with other neuropathies
Similar burning or tingling symptoms do not make different neuropathies interchangeable. ARA-290 research is most useful when its study populations and outcomes are matched carefully to the clinical question.
Read article
Peptides9 min read
ARA-290 and corneal nerve imaging: what an eye scan can tell us
Why nerve trials examine the cornea, what the images measure, and how ARA-290's structural findings differ from pain relief.
Read article434–445 of 600 articles